Stock Track | Intellia Therapeutics Plummets 5.05% as Analyst Cuts Price Target

Stock Track

Mar 04, 2025

Shares of Intellia Therapeutics (NTLA) plunged 5.05% on Monday, March 3rd, during the intraday trading session. The biotech company's stock experienced a significant decline following an analyst's move to lower the price target.

Truist analyst Joon Lee cut the firm's price target on Intellia Therapeutics from $90 to $50, reflecting a significant downward revision. However, Lee maintained a Buy rating on the stock, indicating potential for future growth despite the near-term concerns.

The analyst's decision to lower the price target appears to have weighed heavily on investor sentiment, triggering the sharp sell-off in Intellia Therapeutics' shares. Market participants will closely monitor the company's developments and any further analyst updates that could influence the stock's trajectory.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1149798009"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1149798009\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1149798009?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-04 02:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1149798009","market":"us","top_or_hot":-1,"title":"Stock Track | Intellia Therapeutics Plummets 5.05% as Analyst Cuts Price Target","media":"Stock Track","content":"<p>Shares of Intellia Therapeutics (NTLA) plunged 5.05% on Monday, March 3rd, during the intraday trading session. The biotech company's stock experienced a significant decline following an analyst's move to lower the price target.</p>\n\n<p>Truist analyst Joon Lee cut the firm's price target on Intellia Therapeutics from $90 to $50, reflecting a significant downward revision. However, Lee maintained a Buy rating on the stock, indicating potential for future growth despite the near-term concerns.</p>\n\n<p>The analyst's decision to lower the price target appears to have weighed heavily on investor sentiment, triggering the sharp sell-off in Intellia Therapeutics' shares. Market participants will closely monitor the company's developments and any further analyst updates that could influence the stock's trajectory.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Intellia Therapeutics Plummets 5.05% as Analyst Cuts Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Intellia Therapeutics Plummets 5.05% as Analyst Cuts Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-03-04 02:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Intellia Therapeutics (NTLA) plunged 5.05% on Monday, March 3rd, during the intraday trading session. The biotech company's stock experienced a significant decline following an analyst's move to lower the price target.</p>\n\n<p>Truist analyst Joon Lee cut the firm's price target on Intellia Therapeutics from $90 to $50, reflecting a significant downward revision. However, Lee maintained a Buy rating on the stock, indicating potential for future growth despite the near-term concerns.</p>\n\n<p>The analyst's decision to lower the price target appears to have weighed heavily on investor sentiment, triggering the sharp sell-off in Intellia Therapeutics' shares. Market participants will closely monitor the company's developments and any further analyst updates that could influence the stock's trajectory.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTLA","symbol_name":"Intellia Therapeutics Inc","start_time":0,"source_url":"","article_id":"1149798009","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1149798009","pubTimestamp":1741027724,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Intellia Therapeutics  plunged 5.05% on Monday, March 3rd, during the intraday trading session. The biotech company's stock experienced a significant decline following an analyst's move to lower the price target.Truist analyst Joon Lee cut the firm's price target on Intellia Therapeutics from $90 to $50, reflecting a significant downward revision. However, Lee maintained a Buy rating on the stock, indicating potential for future growth despite the near-term concerns.The analyst's decis","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTLA":"Intellia Therapeutics Inc"},"translate_title":"分析师下调目标价，Intellia Therapeutics股价暴跌5.05%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTLA":1},"content_text":"Shares of Intellia Therapeutics (NTLA) plunged 5.05% on Monday, March 3rd, during the intraday trading session. The biotech company's stock experienced a significant decline following an analyst's move to lower the price target.\nTruist analyst Joon Lee cut the firm's price target on Intellia Therapeutics from $90 to $50, reflecting a significant downward revision. However, Lee maintained a Buy rating on the stock, indicating potential for future growth despite the near-term concerns.\nThe analyst's decision to lower the price target appears to have weighed heavily on investor sentiment, triggering the sharp sell-off in Intellia Therapeutics' shares. Market participants will closely monitor the company's developments and any further analyst updates that could influence the stock's trajectory.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}